Matinas BioPharma (OTCQB: MTNB) is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, according to the company’s website (see here: www.matinasbiopharma.com). SNNLive caught up with Jerry Jabbour, President and Co-Founder of Matinas BioPharma, Inc. at the Dawson James Small Cap Growth Conference 2016 in Jupiter, FL.
In this video interview, Mr. Jabbour and our host discuss the following topics:
- Overview of Matinas BioPharma, Inc.
- How the company’s platform technology works
- Discusses the company’s lead product
- Infectious diseases in the news
- Clinical development update
- Fast track designation
- Mr. Jabbour’s background
- Where science was developed
- Milestones for 2017-2018
For more information about Matinas BioPharma, Inc., please visit: www.matinasbiopharma.com
The interview may contain forward-looking statements about Matinas BioPharma, Inc. See Matinas BioPharma's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions